EnVVeno Medical Corporation (NASDAQ:NVNO)

BRIEF

published on 06/21/2024 at 14:40, 5 months ago

Positive Interim Results for enVVeno Medical’s VenoValve in SAVVE Trial

FDA Approval VenoValve SAVVE Trial Venous Ulcers
PRESS RELEASE

published on 06/21/2024 at 14:35, 5 months ago

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
Veno Medical Corporation presents positive interim data on VenoValve for venous ulcer healing at Society for Vascular Surgery meeting. Company aims for FDA approval in Q4 2024

FDA Approval VenoValve Venous Ulcers Veno Medical Corporation SAVVE U.S. Pivotal Trial
BRIEF

published on 06/17/2024 at 18:05, 5 months 3 days ago

New Interim Venous Ulcer Healing Data from enVVeno Medical VenoValve Trial to be Presented at VAM2024

EnVVeno Medical VenoValve SAVVE Trial Venous Ulcer VAM2024
PRESS RELEASE

published on 06/17/2024 at 18:00, 5 months 3 days ago

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
enVVeno Medical Corporation to present new interim venous ulcer healing data from VenoValve U.S. trial at VAM2024. Study focuses on treatment of venous disease with innovative bioprosthetic solutions

VenoValve EnVVeno Medical Corporation Venous Disease SAVVE Study Vascular Annual Meeting 2024
BRIEF

published on 05/08/2024 at 20:45, 6 months 12 days ago

EnVVeno Medical Reports Promising First Quarter 2024 Results and Upcoming FDA Filings

Medical Devices Clinical Data EnVVeno Medical Q1 2024 Financial Results VenoValve FDA Approval
PRESS RELEASE

published on 05/08/2024 at 20:40, 6 months 12 days ago

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
enVVeno Medical Corporation reported ending the quarter with $42.9 million cash and investments to fund operations through 2025, presenting positive data at the 46th Annual Charing Cross Symposium

Financial Results EnVVeno Medical Corporation SAVVE Trial Venous Disease VenoValve FDA Approval
BRIEF

published on 04/24/2024 at 12:20, 6 months 27 days ago

Significant Clinical Improvements Reported in enVVeno Medical's VenoValve Pivotal Trial

FDA Approval Clinical Trial VenoValve Charing Cross Symposium Venous Disease
PRESS RELEASE

published on 04/24/2024 at 12:15, 6 months 27 days ago

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
enVVeno Medical presents positive efficacy data on VenoValve from SAVVE U.S. pivotal trial at Charing Cross International Symposium, showing clinical improvement for severe CVI patients

FDA Approval VenoValve SAVVE Trial CVI Patients Venous Disease
BRIEF

published on 04/16/2024 at 15:05, 7 months 5 days ago

EnVVeno Medical to Present New VenoValve Efficacy Data at Charing Cross Symposium

Clinical Trials EnVVeno Medical VenoValve Chronic Venous Insufficiency Charing Cross Symposium
PRESS RELEASE

published on 04/16/2024 at 15:00, 7 months 5 days ago

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation

VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium

Published on 11/21/2024 at 16:30, 40 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 1 hour 9 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 1 hour 10 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 1 hour 10 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 1 hour 10 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 1 hour 10 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 1 hour 28 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 1 hour 46 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 47 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 48 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 10 hours 12 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 21 hours 50 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 23 hours 25 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 23 hours 25 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 9 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE

News